Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Intensifying platelet inhibition--navigating between Scylla and Charybdis.

× No keyword cloud information.

30 in total

1. [Panta rhei : blood, professional career and anesthesiological self-conception].

Authors: K Görlinger
Journal: Anaesthesist Date: 2012-06 Impact factor: 1.041

Review 2. The evolution of antiplatelet therapy in cardiovascular disease.

Authors: Omair Yousuf; Deepak L Bhatt
Journal: Nat Rev Cardiol Date: 2011-07-12 Impact factor: 32.419

3. Prasugrel versus clopidogrel in acute coronary syndrome patients undergoing percutaneous coronary intervention.

Authors: Deepak L Bhatt
Journal: Curr Atheroscler Rep Date: 2008-10 Impact factor: 5.113

Review 4. Pre PCI hospital antithrombotic therapy for ST elevation myocardial infarction: striving for consensus.

Authors: S Michael Gharacholou; Brenda J Larson; Christian C Zuver; Ryan J Wubben; Giorgio Gimelli; Amish N Raval
Journal: J Thromb Thrombolysis Date: 2012-07 Impact factor: 2.300

Review 5. Managing adverse effects and drug-drug interactions of antiplatelet agents.

Authors: Arun Kalyanasundaram; A Michael Lincoff
Journal: Nat Rev Cardiol Date: 2011-09-13 Impact factor: 32.419

6. Antiplatelet therapy: Does prasugrel or ticagrelor suffice in patients with STEMI?

Authors: Kush Agrawal; Deepak L Bhatt
Journal: Nat Rev Cardiol Date: 2013-01-15 Impact factor: 32.419

Review 7. Antithrombotic Therapy After Percutaneous Coronary Intervention in Atrial Fibrillation: The Triple Trouble.

Authors: Massimo Leggio; Augusto Fusco; Paolo Severi; Mario Lombardi; Elisa Caldarone; Stefania D'Emidio; Massimo Armeni; Daniela Mereu; Maria Grazia Bendini; Andrea Mazza
Journal: Drugs Date: 2018-09 Impact factor: 9.546

Review 8. Expanding the recognition and assessment of bleeding events associated with antiplatelet therapy in primary care.

Authors: Marc Cohen
Journal: Mayo Clin Proc Date: 2009-02 Impact factor: 7.616

9. Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease.

Authors: Shinya Goto; Hisao Ogawa; Masaru Takeuchi; Marcus D Flather; Deepak L Bhatt
Journal: Eur Heart J Date: 2010-08-30 Impact factor: 29.983

10. Loss of matrix metalloproteinase 2 in platelets reduces arterial thrombosis in vivo.

Authors: Stefania Momi; Emanuela Falcinelli; Silvia Giannini; Loredana Ruggeri; Luca Cecchetti; Teresa Corazzi; Claude Libert; Paolo Gresele
Journal: J Exp Med Date: 2009-10-05 Impact factor: 14.307